Sutro Biopharma

Business news, market intelligence, and global industry analysis.

The Latest

What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC

Delivery Hero (DHER) stock up 4% to €29.5 as Aspex forces CEO exit and Korea sale opens

What the RIDGE-1 interim results reveal about the future of cardiac gene therapy in ARVC

Hanwha Aerospace targets NATO demand with Romania unmanned systems push at BSDA 2026

What Sutro Biopharma’s restructuring says about biotech layoffs and investor sentiment in 2025

Sutro Biopharma (NASDAQ: STRO) slashes jobs and narrows its pipeline to extend cash runway into 2027. What does this restructuring mean for investors?

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures

September 30, 2025